Lumova

1. Innovative Device for Diagnosis of Visual Neural
Deficiency Amblyopia
January, 2020
Contact:
George Hu, Ph.D.
CEO
Tel: (908) 803-7040
ghu@lumovamedical.com

2. Amblyopia in the U.S.
• Most common cause of monocular (one eye) visual impairment
• There are over 20 million children under 5 years old who need to be properly
examined
• Impacts children’s learning and social development
• 3% of children are affected by amblyopia and many are not detected
Current diagnostic methods are not efficient
• The devices used by clinicians today, photoscreen and autorefractor, are only for
amblyopia risk factor assessment, and they cannot assess amblyopia directly
• Not all risks will lead to amblyopia
Eye disease early detection is crucial
• Early diagnosis can result in successful treatment and prevent permanent damage
1
Current Problem

3. Solution: eMox
The Product
• eMox is a medical instrument for amblyopia detection and treatment monitoring
• Only device that can detect amblyopia directly in clinic environment
• Compact, non-invasive, hand-held for operation
• Produces automatic test result “Pass” and “Fail” and quantitative measure for severity
Technologies
• Electrooculogram (EOG) is generated by
the movement of an eye following an
object on the screen
• OKN sawtooth waveforms exist in EOG
signal, which can diagnose amblyopia
• DVTF, an AI pattern recognition
algorithm and patent pending
technology, can identify OKN
2

4. Ophthalmologists: 19,200
Optometrists: 40,000
Pediatricians: 58,700
Total eye-care professionals: 117,900
Potential market ($20,000 per unit): 2,350,000,000
Units placed (20.0% of total physicians): 23,580
Targeted market ($20,000 per unit): 471,600,000
Customers and Market Size
3

5. George Hu, Ph.D., Chief Executive Officer, Founder of Lumova
• Inventor of patent pending technology DVTF equipped in eMox device
• Formed a medical device companies VeriSci Corporation and a joint venture
HMMT Ltd. in Huzhou, China.
• Sold and leased over 800 devices in ophthalmic and research fields.
• Organized multi-site clinical trials
• Successfully obtained FDA 510(k) clearance for marketing medical device
• Received awards three times from the National Institutes of Health for
innovations in medical products.
• Ph.D. in Electrical Engineering from New Jersey Institute of Technology with
thesis research at Rockefeller University, New York.
Management
4

6. New York Eye and Ear Infirmary of Mount Sinai, New York City, New York
Eye Clinic, University of Virginia School of Medicine, Charlottesville, Virginia
New England Eye Center, Tufts University School of Medicine, Boston, Massachusetts
Potential Sites for Clinical Trial
5

7. Amblyopia Risk Factors
Amblyopia
Refractive
Strabismic
Deprivation
COMPANY PRODUCT TECHNOLOGY DIAGNOSIS
Plusoptix S12C Autorefract Risk Factors
Plusoptix A12C Photoscreen Risk Factors
Welch Allyn Spot Autorefract Risk Factors
Gobiquity GoCheck Kids Photoscreen Risk Factors
Rebion Blinq Photoscreen Risk Factors
Lumova eMox OKN/DVTF Amblyopia
Competition
6

8. Current state
• Completed Prototype
• Filed patent applications for DVTF technology in US and China
First year focus after funding
• Complete product
• Obtain FDA 510 (k) marketing clearance
• Complete clinical trial
Second year planning after funding
• Launch sales
Accomplishments, Focus, and Planning
7

9. Revenue
Expenses
YEAR1st 2nd 3rd 4th
570K
2.17M
6M
11.22M
2.4M
7.92M
15.84M
Financial Projections
8

10. • Market need for early stage amblyopia diagnosis
• Targeted market: $470M
• eMox is the only device for direct assessment of amblyopia
• Patent pending AI technology for pattern recognition
• Existing CPT Codes for reimbursement in every state
• Execution by experienced management team
• Raising $750K to make the product marketable
• Advantage of investment: Short waiting period for sales launch
Summary
9